NK cell study for leukemia or myelodysplasia patients
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at natural killer (NK) cells, a type of immune cell, in patients with acute leukemia or myelodysplastic syndrome who are getting a stem cell transplant. It aims to understand how these cells change over time and may help predict outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome
- You are receiving a stem cell transplant (from a donor)
- You may or may not be receiving a drug called azacitidine (AZA) after transplant
- You are willing to sign a consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy using natural killer cells (immune cells that fight cancer) given after a stem cell transplant in children with leukemia or neuroblastoma. The goal is to see if these cells help prevent cancer from coming back and are safe for young patients.
This trial tests a customized immune-cell treatment (NK cells) for certain blood cancers to try to control or eliminate cancer cells. You may qualify if your cancer has come back, did not fully respond, or has higher risk features.
This trial tests whether a special immune cell infusion (NK cells) from a half-matched family donor can help keep your AML in remission after initial chemotherapy. It is meant for people who have recently achieved their first remission and are otherwise healthy enough for a second round of chemo.
This trial tests whether giving specially trained natural killer (NK) cells after a stem cell transplant can help prevent relapse in people with high-risk blood cancers like AML, MDS, or MDS/MPN. You receive one infusion of these cells about a week after your transplant.
This trial tests a new natural killer (NK) cell therapy for adults with acute myeloid leukemia (AML) that has returned or not responded to treatment. The therapy targets two specific markers (CLL1 or CD33) on leukemia cells. It aims to see if these immune cells can safely fight the cancer.
This trial tests a new treatment using special immune cells (called natural killer cells) made from stem cells to fight acute myeloid leukemia (AML) that has come back or not responded to other treatments. The goal is to see if these cells can safely help control or eliminate the leukemia.
Hear when a new Leukaemia (Acute Myeloid) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.